These data suggest that ARHGEF12 E620K mutation represents a gain-of-function mutation, enhancing the invasive potential of gastric cancer cells through hyperactivation of the canonical GTPase RhoA. This evidence concerns the gene ARHGEF12 and gastric cancer.